{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05660967\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EPCORE DLBCL-3","nct_id":"NCT05660967","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=epcore-dlbcl-3-nct05660967. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EPCORE DLBCL-3","arms":[{"description":null,"label":"Epcoritamab monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"Epcoritamab in combination with lenalidomide","type":"EXPERIMENTAL"}],"collaborators":["AbbVie"],"completion_date":{"date":"2026-06-10","type":"ACTUAL"},"conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":{"count":111,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Epcoritamab","otherNames":["GEN3013","DuoBody®-CD3×CD20","EPKINLY™"],"type":"BIOLOGICAL"},{"name":"Lenalidomide","otherNames":["Revlimid®"],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Genmab","official_title":"Efficacy and Safety of Epcoritamab Monotherapy and in Combination With Lenalidomide as First-line Therapy for Anthracycline-ineligible Diffuse Large B-Cell Lymphoma Patients, an Open-label, Randomized, Multicenter, Global Phase 2 Trial","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-06-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response (CR) rate","timeFrame":"From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years"}],"references":[{"citation":"Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, Lopez-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH. Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial. Lancet Haematol. 2026 Jul;13(7):e435-e448. doi: 10.1016/S2352-3026(26)00112-2. Epub 2026 Jun 12.","pmid":"42285113","type":"DERIVED"}],"start_date":{"date":"2023-03-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT05660967"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/epcore-dlbcl-3-nct05660967"}